U.S. Physical Therapy, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy USPH?
Source: seekingalpha
- Strong Financial Performance: For the year ending 2025, adjusted EBITDA increased by $13.2 million, a 16.2% improvement, and net revenue rose by 16.3%, demonstrating significant financial progress despite ongoing Medicare rate reductions.
- Acquisitions and Strategic Partnerships: The company has made several acquisitions in the Pacific Northwest and New York City, with hospital partnerships expected to contribute at least $14 million to EBITDA by 2027, further strengthening its market position.
- 2026 Outlook: Management expects adjusted EBITDA for 2026 to be in the range of $102 million to $106 million, including $2.5 million from Medicare revenue increases, reflecting confidence in future growth.
- Operational Efficiency Gains: Average visits per clinic per day reached 32.7 in Q4, a record high for the company, with total patient visits growing 11.2% year-over-year, indicating significant improvements in customer service and operational efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy USPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on USPH
Wall Street analysts forecast USPH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 80.570
Low
100.00
Averages
101.50
High
103.00
Current: 80.570
Low
100.00
Averages
101.50
High
103.00
About USPH
U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 774 outpatient physical therapy clinics in 44 states. It operates through the Physical Therapy Operations and Industrial Injury Prevention Services segments. The Physical Therapy Operations segment consists of physical therapy and occupational therapy clinics that provide pre and post operative care and treatment for orthopedic related disorders, sports-related injuries, preventive care, rehabilitation of injured workers and neurological injuries. The Industrial Injury Prevention Services segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Complete Exit: 4D Advisors disclosed in a SEC filing that it fully exited its stake in U.S. Physical Therapy by selling 110,000 shares in Q4 2026, resulting in a $9.34 million decline in position value, indicating a loss of investor confidence in the stock.
- Flat Stock Performance: As of February 17, 2026, U.S. Physical Therapy shares were priced at $86.54, reflecting only a 0.2% increase over the past year, which, in the context of a rising broader market, suggests relative underperformance that may prompt investors to reassess their opportunity costs.
- Lackluster Financial Growth: The latest earnings report showed revenue growth of over 16% to approximately $173.8 million; however, concerns over declining year-over-year profitability led to a 12% drop in shares, highlighting market apprehension regarding future earnings potential.
- Strategic Shift Indication: The complete exit by 4D Advisors signals that the investment no longer met return hurdles, particularly amid increased stock volatility, while CEO Chris Reading pointed to potential long-term value from acquisitions and new hospital relationships, although short-term stock performance remains under pressure.
See More
- Industry Performance Overview: In the outpatient and specialty care sector, the seven tracked stocks reported Q4 revenues exceeding analysts' expectations by 2.5%, indicating the industry's stability and attractiveness amid rising healthcare costs.
- U.S. Physical Therapy Growth: U.S. Physical Therapy reported revenues of $202.7 million, a 12.3% year-over-year increase that surpassed analysts' expectations by 1.7%, reflecting progress in key initiatives, although EPS was in line with forecasts.
- DaVita Strong Performance: DaVita's revenue reached $3.62 billion, up 9.9% year-over-year, exceeding analysts' expectations by 3.2%, with its stock rising 36.7% since reporting, showcasing market confidence in its robust performance.
- Surgery Partners Ongoing Challenges: Surgery Partners reported revenues of $885 million, a 2.4% year-over-year increase that exceeded expectations by 1.9%, but its full-year revenue and EBITDA guidance significantly missed analysts' forecasts, resulting in a 13.3% drop in stock price.
See More

- Strong Financial Performance: For the year ending 2025, adjusted EBITDA increased by $13.2 million, a 16.2% improvement, and net revenue rose by 16.3%, demonstrating significant financial progress despite ongoing Medicare rate reductions.
- Acquisitions and Strategic Partnerships: The company has made several acquisitions in the Pacific Northwest and New York City, with hospital partnerships expected to contribute at least $14 million to EBITDA by 2027, further strengthening its market position.
- 2026 Outlook: Management expects adjusted EBITDA for 2026 to be in the range of $102 million to $106 million, including $2.5 million from Medicare revenue increases, reflecting confidence in future growth.
- Operational Efficiency Gains: Average visits per clinic per day reached 32.7 in Q4, a record high for the company, with total patient visits growing 11.2% year-over-year, indicating significant improvements in customer service and operational efficiency.
See More
- Oversold Status: U.S. Physical Therapy, Inc. (USPH) has an RSI of 27.8, indicating it has entered oversold territory below the 30 threshold, suggesting that recent selling pressure may be exhausting, thus presenting potential buying opportunities for investors.
- Dividend Yield: The company's recent annualized dividend of $1.84 per share translates to an annual yield of 2.25% based on the current share price of $81.68, making it attractive for dividend-seeking investors.
- Market Comparison: Compared to the average RSI of 54.2 for dividend stocks covered by Dividend Channel, USPH's significantly lower RSI indicates that its stock price may be undervalued, potentially drawing more investor interest.
- Investor Strategy: While dividends are not always predictable, examining USPH's dividend history can assist investors in assessing the likelihood of continued dividend payments, enabling more informed investment decisions.
See More
- Quarterly Dividend Increase: U.S. Physical Therapy has declared a quarterly dividend of $0.46 per share, marking a 2.2% increase from the previous $0.45, reflecting the company's ongoing improvement in cash flow stability and profitability, which boosts investor confidence.
- Positive Earnings Outlook: The company exceeded top-line estimates in its earnings report and provided a favorable outlook for FY26, indicating strong business growth potential that is likely to enhance shareholder returns and market recognition.
- Strategic Acquisition: U.S. Physical Therapy acquired an industrial injury prevention business for $15.1 million, aiming to expand its service offerings and market share, thereby strengthening its competitive position in the healthcare sector.
- Shareholder Return Commitment: The dividend will be payable on April 10, with a record date of March 13, demonstrating the company's commitment to consistently rewarding shareholders and enhancing shareholder value.
See More








